Literature DB >> 7814613

Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance.

T Münzel1, H Sayegh, B A Freeman, M M Tarpey, D G Harrison.   

Abstract

We sought to examine mechanisms underlying nitroglycerin (NTG) tolerance and "cross-tolerance" to other nitrovasodilators. Rabbits were treated for 3 d with NTG patches (0.4 mg/h) and their aortic segments studied in organ chambers. Relaxations were examined after preconstriction with phenylephrine. In NTG tolerant rabbit aorta, relaxations to cGMP-dependent vasodilators such as NTG (45 +/- 6%), SIN-1 (69 +/- 7%), and acetylcholine (ACh, 64 +/- 5%) were attenuated vs. controls, (90 +/- 2, 94 +/- 3, and 89 +/- 2% respectively, P < 0.05 for all), while responses to the cAMP-dependent vasodilator forskolin remained unchanged. In tolerant aorta, endothelial removal markedly enhanced relaxations to NTG and SIN-1 (82 +/- 4 and 95 +/- 3%, respectively). Other studies were performed to determine how the endothelium enhances tolerance. Vascular steady state .-O2 levels (assessed by lucigenin chemiluminescence) was increased twofold in tolerant vs. control vessels with endothelium (0.31 +/- 0.01 vs. 0.61 +/- 0.01 nmol/mg per minute). This difference was less in vessels after denudation of the endothelium. Diphenylene iodonium, an inhibitor of flavoprotein containing oxidases, and Tiron a direct .-O2 scavenger normalized .-O2 levels. In contrast, oxypurinol (1 mM) an inhibitor of xanthine oxidase, rotenone (50 microM) an inhibitor of mitochondrial electron transport and NG-nitro-L-arginine (100 microM) an inhibitor of nitric oxide synthase did not affect the chemiluminescence signals from NTG-tolerant aortas. Pretreatment of tolerant aorta with liposome-entrapped, pH sensitive superoxide dismutase (600 U/ml) significantly enhanced maximal relaxation in response to NTG, SIN-1, and ACh, and effectively reduced chemiluminescence signals. These studies show that continuous NTG treatment is associated with increased vascular .-O2-production and consequent inhibition of NO. mediated vasorelaxation produced by both exogenous and endogenous nitrovasodilators.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7814613      PMCID: PMC295403          DOI: 10.1172/JCI117637

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Specific labelling of a constituent polypeptide of bovine heart mitochondrial reduced nicotinamide-adenine dinucleotide-ubiquinone reductase by the inhibitor diphenyleneiodonium.

Authors:  C I Ragan; D P Bloxham
Journal:  Biochem J       Date:  1977-06-01       Impact factor: 3.857

2.  Diphenylene iodonium as an inhibitor of the NADPH oxidase complex of bovine neutrophils. Factors controlling the inhibitory potency of diphenylene iodonium in a cell-free system of oxidase activation.

Authors:  J Doussière; P V Vignais
Journal:  Eur J Biochem       Date:  1992-08-15

3.  Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin.

Authors:  J D Parker; B Farrell; T Fenton; M Cohanim; J O Parker
Journal:  Circulation       Date:  1991-12       Impact factor: 29.690

4.  Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells.

Authors:  S J Chung; H L Fung
Journal:  J Pharmacol Exp Ther       Date:  1990-05       Impact factor: 4.030

5.  Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein).

Authors:  J M McCord; I Fridovich
Journal:  J Biol Chem       Date:  1969-11-25       Impact factor: 5.157

6.  Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.

Authors:  G B Elion; A Kovensky; G H Hitchings
Journal:  Biochem Pharmacol       Date:  1966-07       Impact factor: 5.858

7.  Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs.

Authors:  D J Stuehr; O A Fasehun; N S Kwon; S S Gross; J A Gonzalez; R Levi; C F Nathan
Journal:  FASEB J       Date:  1991-01       Impact factor: 5.191

8.  Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase.

Authors:  B V O'Donnell; D G Tew; O T Jones; P J England
Journal:  Biochem J       Date:  1993-02-15       Impact factor: 3.857

9.  L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro.

Authors:  P K Moore; O A al-Swayeh; N W Chong; R A Evans; A Gibson
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

10.  Superoxide radical and superoxide dismutases: threat and defense.

Authors:  K Brawn; I Fridovich
Journal:  Acta Physiol Scand Suppl       Date:  1980
View more
  121 in total

Review 1.  Reactive oxygen and nitrogen species in pulmonary hypertension.

Authors:  Diana M Tabima; Sheila Frizzell; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2012-03-06       Impact factor: 7.376

Review 2.  After 130 years, the molecular mechanism of action of nitroglycerin is revealed.

Authors:  Louis J Ignarro
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

Review 3.  Age-related endothelial dysfunction : potential implications for pharmacotherapy.

Authors:  Rachel L Matz; Ramaroson Andriantsitohaina
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

4.  Ozonized autohemotransfusion does not affect arterial vasodilation in patients with peripheral arterial disease.

Authors:  Antonino Coppola; Ludovico Coppola; Carlo Luongo; Alessandro Arciello; Federico Cacciapuoti; Diana Lama; Margherita Luongo; Luigi Ruggiero; Agostino Pastore; Giorgio Gombos
Journal:  Int J Angiol       Date:  2007

5.  Daily low-dose folic acid supplementation does not prevent nitroglycerin-induced nitric oxide synthase dysfunction and tolerance: a human in vivo study.

Authors:  Jonathan M DiFabio; Tommaso Gori; George Thomas; Sean Jedrzkiewicz; John D Parker
Journal:  Can J Cardiol       Date:  2010-11       Impact factor: 5.223

Review 6.  Crosstalk between endothelin and nitric oxide in the control of vascular tone.

Authors:  M Lavallée; M Takamura; R Parent; E Thorin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

7.  Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure.

Authors:  J A Bauer; J P Balthasar; H L Fung
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

8.  Arginase II inhibition prevents nitrate tolerance.

Authors:  S M L Khong; K L Andrews; N N Huynh; K Venardos; A Aprico; D L Michell; M Zarei; K T Moe; G J Dusting; D M Kaye; J P F Chin-Dusting
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

9.  Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats.

Authors:  Ellen Q Wang; Ho-Leung Fung
Journal:  AAPS PharmSci       Date:  2002

10.  Characteristics of attenuated endothelium-dependent relaxation seen in rabbit intrapulmonary vein following chronic nitroglycerine administration.

Authors:  Nobuyoshi Kusama; Junko Kajikuri; Yoshimasa Watanabe; Yoshikatsu Suzuki; Hirotada Katsuya; Takeo Itoh
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.